Safety of beta-adrenergic blocker washout period in clinical trials.
We prospectively evaluated the safety of the washout period from topical beta-adrenergic blockers prior to clinical drug trials. In 30 consecutive patients optic disc parameters (neural rim, optic disc, peripapillary halo and atrophy areas, and venous/arterial diameters) did not change following washout (p > 0.05). Likewise, the mean defect and pattern standard deviation (Humphrey 30-2) did not change following washout (p > 0.05). This study suggests, generally, the safety of the washout period prior to clinical drug trials.
Stroman
G A
GA
Medical University of South Carolina, Charleston, USA.
Stewart
W C
WC
Stewart
J A
JA
Deitz
T M
TM
D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic / Q000379:methods*; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D009883:Ophthalmic Solutions; D009898:Optic Disk / Q000187:drug effects; D011446:Prospective Studies; D012449:Safety; D014794:Visual Fields / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D009883:Ophthalmic Solutions